 "FDC at 52-wk high as Goa plant gets GMP certificate from UK drug regulator")
Shares of FDC hit a 52-week high of Rs 222 on the BSE after rallying 5 per cent in intra-day trade on Friday in an otherwise range-bound market after the drug company received good manufacturing practice (GMP) certificate from UK drug regulator for its Goa plant. The stock surpassed its previous high of Rs 220, recorded on May 27, 2019.
“The Company has received GMP certificate and it continues with its approved status from UK MHRA (Medicines and Healthcare Products Regulatory Agency), for two of its Oral solid Dosage form facilities situated at L-56/57 and L-121 in Verna, Goa,” FDC said in an exchange filing.
The certificate issued on recent GMP inspection was held at the said plants, it said.
In the past two months, FDC has outperformed the market by surging 25 per cent, after reporting a healthy September quarter earnings (Q2FY20). In comparison, the S&P BSE Sensex was up 3 per cent during the same period.
The company had reported 42 per cent year on year (Y-o-Y) jump in its consolidated net profit at Rs 80.38 crore in Q2FY20, against Rs 56.70 crore in the year-ago quarter. Operational revenue rose 26 per cent to Rs 346 crore on Y-o-Y basis. EBITDA (earnings before interest, tax, depreciation and amortisation) margin improved to 21.3 per cent from 20.9 per cent during the quarter.
At 10:40 am, the stock was trading 2 per cent higher at Rs 216 on the BSE, against 0.27 per cent fall in the benchmark index. A combined 83,252 equity shares have changed hands on the counter on the NSE and BSE so far.
“The Company has received GMP certificate and it continues with its approved status from UK MHRA (Medicines and Healthcare Products Regulatory Agency), for two of its Oral solid Dosage form facilities situated at L-56/57 and L-121 in Verna, Goa,” FDC said in an exchange filing.
The certificate issued on recent GMP inspection was held at the said plants, it said.
In the past two months, FDC has outperformed the market by surging 25 per cent, after reporting a healthy September quarter earnings (Q2FY20). In comparison, the S&P BSE Sensex was up 3 per cent during the same period.
The company had reported 42 per cent year on year (Y-o-Y) jump in its consolidated net profit at Rs 80.38 crore in Q2FY20, against Rs 56.70 crore in the year-ago quarter. Operational revenue rose 26 per cent to Rs 346 crore on Y-o-Y basis. EBITDA (earnings before interest, tax, depreciation and amortisation) margin improved to 21.3 per cent from 20.9 per cent during the quarter.
At 10:40 am, the stock was trading 2 per cent higher at Rs 216 on the BSE, against 0.27 per cent fall in the benchmark index. A combined 83,252 equity shares have changed hands on the counter on the NSE and BSE so far.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%